← All trials
NCT06788626
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 28, 2025
- Primary completion
- Feb 29, 2028
- Completion date
- Feb 29, 2028
- First posted
- Jan 23, 2025
- Last posted
- Jan 23, 2025
- Enrollment
- 390
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of Science and Technology of ChinaLead sponsor
- Chinese University of Hong KongCollaborator
- University of Science and Technology of ChinaSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.